Gemcitabine combined with a chemokine receptor CCR2 or CSF-1 receptor inhibitor to reduce the number of TAMs in pancreatic TME increases the number of CD8+T lymphocytes, reduces FOXP3+ Treg lymphocytes and inhibits the development of pancreatic cancer, indicating that reducing TAMs increases the responsiveness of pancreatic cancer to anti-tumor immunity (95, 96). Here, CD8A is linked to familial pancreatic carcinoma.